NeuroPace Strengthens Management Team with Two Key Appointments
NeuroPace (NPCE) has strengthened its management team with two key appointments. Brett Wingeier joins as the new Vice President of Research and Development, bringing over 20 years of experience in neurotech and biomedical engineering, including a decade as a key contributor to the development of NeuroPace's RNS System. Katie Keller has been appointed as the new Vice President of Marketing, bringing significant experience in medical device marketing, particularly from her role leading the global commercial marketing for Boston Scientific's Neuromodulation Deep Brain Stimulation franchise.
These appointments aim to enhance NeuroPace's market development programs, drive broader adoption of RNS therapy, and advance the company's strategy to expand the capabilities of the RNS System. Both executives express excitement about joining NeuroPace and contributing to its mission of transforming the lives of people living with epilepsy.
NeuroPace (NPCE) ha rafforzato il suo team di gestione con due nomine chiave. Brett Wingeier entra come nuovo Vicepresidente della Ricerca e Sviluppo, portando oltre 20 anni di esperienza nel settore delle neurotecnologie e dell'ingegneria biomedica, inclusi dieci anni come contributore principale allo sviluppo del Sistema RNS di NeuroPace. Katie Keller è stata nominata nuova Vicepresidente del Marketing, con un'importante esperienza nel marketing di dispositivi medici, in particolare nel ruolo di leader del marketing commerciale globale per il franchise di Stimolazione Cerebrale Profonda di Boston Scientific.
Queste nomine mirano a migliorare i programmi di sviluppo del mercato di NeuroPace, favorire una più ampia adozione della terapia RNS e avanzare la strategia dell'azienda per espandere le capacità del Sistema RNS. Entrambi i dirigenti esprimono entusiasmo per essere entrati a far parte di NeuroPace e per contribuire alla sua missione di trasformare le vite delle persone che vivono con l'epilessia.
NeuroPace (NPCE) ha fortalecido su equipo directivo con dos nombramientos clave. Brett Wingeier se une como el nuevo Vicepresidente de Investigación y Desarrollo, aportando más de 20 años de experiencia en neurotecnología e ingeniería biomédica, incluyendo una década como contribuyente clave en el desarrollo del Sistema RNS de NeuroPace. Katie Keller ha sido nombrada nueva Vicepresidenta de Marketing, trayendo una amplia experiencia en marketing de dispositivos médicos, especialmente de su papel liderando el marketing comercial global para la franquicia de Estimulación Cerebral Profunda de Boston Scientific.
Estos nombramientos tienen como objetivo mejorar los programas de desarrollo de mercado de NeuroPace, fomentar una adopción más amplia de la terapia RNS y avanzar en la estrategia de la empresa para expandir las capacidades del Sistema RNS. Ambos ejecutivos expresan su entusiasmo por unirse a NeuroPace y contribuir a su misión de transformar las vidas de las personas que viven con epilepsia.
NeuroPace (NPCE)는 두 가지 주요 인사로 경영진을 강화했습니다. Brett Wingeier는 연구 및 개발의 새로운 부사장으로 합류하며, 신경기술 및 생의학 공학에서 20년 이상의 경험을 보유하고 있으며, NeuroPace의 RNS 시스템 개발에 주요 기여자로 10년을 보냈습니다. Katie Keller는 의료 기기 마케팅 분야에서 상당한 경험을 가진 새로운 마케팅 부사장으로 임명되었으며, 특히 Boston Scientific의 신경 조절 심부 뇌 자극 브랜드의 글로벌 상업 마케팅을 이끌었던 역할에서의 경험이 있습니다.
이러한 인사는 NeuroPace의 시장 개발 프로그램을 강화하고 RNS 치료의 넓은 채택을 촉진하며 RNS 시스템의 기능을 확장하는 회사 전략을 발전시키는 것을 목표로 합니다. 두 임원 모두 NeuroPace에 합류하게 된 것에 대해 흥분을 표명하며, 간질을 앓고 있는 사람들의 삶을 변화시키기 위한 미션에 기여할 수 있게 되어 기쁩니다.
NeuroPace (NPCE) a renforcé son équipe de direction avec deux nominations clés. Brett Wingeier rejoint en tant que nouveau Vice-président de la Recherche et du Développement, apportant plus de 20 ans d'expérience dans la neurotechnologie et l'ingénierie biomédicale, dont une décennie en tant que contributeur clé au développement du Système RNS de NeuroPace. Katie Keller a été nommée nouvelle Vice-présidente du Marketing, apportant une expérience significative dans le marketing de dispositifs médicaux, notamment dans son rôle de direction du marketing commercial mondial pour la franchise de Stimulation Cérébrale Profonde de Boston Scientific.
Ces nominations visent à améliorer les programmes de développement de marché de NeuroPace, à favoriser une adoption plus large de la thérapie RNS et à faire avancer la stratégie de l'entreprise pour étendre les capacités du Système RNS. Les deux cadres expriment leur enthousiasme à rejoindre NeuroPace et à contribuer à sa mission de transformation des vies des personnes vivant avec l'épilepsie.
NeuroPace (NPCE) hat sein Management-Team mit zwei wichtigen Ernennungen gestärkt. Brett Wingeier tritt als neuer Vizepräsident für Forschung und Entwicklung bei, bringt über 20 Jahre Erfahrung in Neurotechnologie und biomedizinischer Technik mit, darunter ein Jahrzehnt als wesentlicher Mitwirkender an der Entwicklung des RNS-Systems von NeuroPace. Katie Keller wurde zur neuen Vizepräsidentin für Marketing ernannt und bringt umfangreiche Erfahrung im Marketing von Medizinprodukten mit, insbesondere aus ihrer Rolle bei der globalen kommerziellen Vermarktung des Neuromodulations-Deep-Brain-Stimulation-Segments von Boston Scientific.
Diese Ernennungen zielen darauf ab, die Marktentwicklungsprogramme von NeuroPace zu verbessern, die breitere Akzeptanz der RNS-Therapie voranzutreiben und die Strategie des Unternehmens zur Erweiterung der Funktionen des RNS-Systems zu fördern. Beide Führungskräfte drücken ihre Begeisterung aus, zu NeuroPace zu stoßen und zur Mission beizutragen, das Leben von Menschen mit Epilepsie zu verändern.
- Appointment of Brett Wingeier as VP of R&D, bringing extensive experience in neurotech and prior involvement with RNS System development
- Appointment of Katie Keller as VP of Marketing, bringing expertise in neurostimulation market and commercial marketing
- Potential for enhanced market development and broader adoption of RNS therapy
- Opportunity for expansion of RNS System capabilities through technology development plans
- None.
Appointed former key developer of RNS System as new Vice President of Research and Development
Appointed former head of commercial marketing for Boston Scientific’s DBS franchise as the new Vice President of Marketing
MOUNTAIN VIEW, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointments of Brett Wingeier as the new Vice President of Research and Development and Katie Keller as the new Vice President of Marketing, effective immediately.
“We are excited to welcome Katie and Brett to our team. Katie brings an understanding of the neurostimulation market and expertise in market development through her tenure at Boston Scientific and leading its DBS commercial marketing function. I’m confident that through her leadership our market development programs and plans will move to the next level as we look to close the treatment gap by driving broader adoption and utilization of RNS therapy,” said Joel Becker, Chief Executive Officer of NeuroPace. “Brett is a proven innovator and developer of advanced medical devices, which includes our RNS technology. His extensive knowledge of the RNS System and epilepsy will position him to help advance our strategy to expand the capabilities of the RNS System through our technology development plans and pipeline.”
“I am excited to join NeuroPace and look forward to working with the team on expanding access to the Company’s life changing RNS therapy through indication expansion and increased awareness with both patients and clinicians,” stated Ms. Keller.
Ms. Keller brings significant experience and a track record of success in medical device marketing and commercial roles to NeuroPace. Most recently, she led the global commercial marketing function for Boston Scientific’s Neuromodulation Deep Brain Stimulation (DBS) franchise. In addition, she brings deep experience in marketing and market development from her leadership roles with a number of device markets, including Interventional Cardiology, Cardiac Physiology and Cardiac Rhythm Management. Ms. Keller received a Masters in Bioscience (MBA/Bioengineering hybrid program) from the Keck Graduate Institute and a Bachelor of Science degree in Biomedical Engineering from the University of Southern California.
“I am excited to rejoin NeuroPace at such an exciting time for the Company and for the RNS System,” said Dr. Wingeier. “The unique monitoring and analysis capabilities of the RNS System have provided us with an unparalleled dataset. I look forward to working with the team and our customers to further evolve these capabilities and translate these data into enhanced ease of use, greater efficiency, and clinical insights that continue to transform the lives of people living with epilepsy.”
Brett brings more than 20 years of experience across neurotech, biomedical engineering and entrepreneurship to the Company, including more than a decade as a key contributor to the development of NeuroPace’s RNS System in the early 2000s. Most recently, Dr. Wingeier served as CEO, CTO and co-founder of Magnus Medical, gaining FDA clearance for a data-driven, individually targeted hardware and software platform with rapid effectiveness in major depression. Prior to Magnus, he served as the CTO, CEO and co-founder of Halo Neuroscience, a venture-backed company focusing on non-invasive neuromodulation for human performance, from 2013 to 2019. Prior to Halo, Dr. Wingeier served as a Principal Engineer at NeuroPace from 2001 to 2013, during which time he was instrumental in projects including development of the RNS System and analysis of the Company’s earliest clinical data. He holds a Bachelor of Science in Engineering and Ph.D. in Biomedical Engineering from Tulane University. Dr. Wingeier is a U.S. registered patent agent with more than 70 issued patents.
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
Forward Looking Statements
This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: NeuroPace’s current expectations, forecasts and beliefs; future financial performance, including management’s continued outlook for fiscal year 2024; the Company’s commitment to effectively managing its operating expenses; ability to capitalize on increased market opportunities by expanding access to treatments; and clinical trial results and indication expansion. NeuroPace may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties related to market acceptance and adoption of NeuroPace’s RNS System; risks related to the pricing of the RNS System and availability of adequate reimbursement for the procedures to implant the RNS System and for clinicians to provide ongoing care for patients treated with the RNS System; the risk that NeuroPace may not realize the intended benefits of its partnership with DIXI Medical; risks related to regulatory compliance and expectations for regulatory approvals to expand the market for NeuroPace’s RNS System; NeuroPace’s reliance on contractors and other third parties, including single-source suppliers and vendors; and other important factors. These and other risks and uncertainties include those described more fully in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in NeuroPace’s public filings with the U.S. Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 13, 2024, as well as any other reports that it may file with the SEC in the future. Forward-looking statements contained in this announcement are based on information available to NeuroPace as of the date hereof. NeuroPace undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing NeuroPace’s views as of any date subsequent to the date of this press release and should not be relied upon as a prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of NeuroPace.
Investor Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
jfeffer@lifesciadvisors.com
FAQ
Who are the new key appointments at NeuroPace (NPCE)?
What is Brett Wingeier's background and how does it relate to NeuroPace (NPCE)?
What experience does Katie Keller bring to her role at NeuroPace (NPCE)?
How are these appointments expected to benefit NeuroPace (NPCE)?
